-transparent.png){kind=logo}
It has been reported that the addition of nonaggregating concentrations of collagen, epinephrine, thrombin or arachidonic acid to platelets potentiate their responses to subsequent subthreshold concentrations of aggregating agents. We have previously reported that low concentrations of methylmercury will potentiate human platelet ATP secretion and that this effect is blocked by aspirin. Using rat platelets we have examined the effect of low concentrations of methylmercury on the metabolism of arachidonic acid. Low concentrations of methylmercury (20-100 microM) inhibit washed platelet lipoxygenase activity. In experiments using platelet rich plasma a higher concentration of methylmercury was required to produce a comparable inhibition of arachidonic acid metabolism. At these concentrations no inhibition of platelet thromboxane synthetase was seen. These findings suggest that methylmercury potentiates platelet aggregation and secretion by reducing the inhibitory effect of 12 HPETE on thromboxane biosynthesis.
A I Ally, and
D R Miller
January 1983,
Transfusion,
A I Ally, and
D R Miller
January 1982,
Advances in prostaglandin, thromboxane, and leukotriene research,
A I Ally, and
D R Miller
August 1980,
Biochemical and biophysical research communications,
A I Ally, and
D R Miller
February 1981,
Prostaglandins,
A I Ally, and
D R Miller
September 1985,
Journal of neurochemistry,
A I Ally, and
D R Miller
December 1983,
Biochemical and biophysical research communications,
A I Ally, and
D R Miller
January 1987,
Advances in prostaglandin, thromboxane, and leukotriene research,
A I Ally, and
D R Miller
October 1984,
Thrombosis research,
A I Ally, and
D R Miller
January 1990,
Advances in prostaglandin, thromboxane, and leukotriene research,
A I Ally, and
D R Miller
September 1976,
The Kumamoto medical journal,
